Neurotrophic factor therapy for Parkinson's disease: past, present and future.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

31 citing papers in PubMed.

1. Simvastatin Protects the Dopaminergic Neurons from MPTP-Mediated Injury by Inducing BDNF via PPARα Activation.Biomolecules & therapeutics · 2026
   Article
2. Redefining Parkinson's Disease management: the synergistic role of neurotrophic factors and mitochondria.Cellular and molecular life sciences : CMLS · 2026
   Review
3. TLR3 activation in astrocytes attenuates the nigrostriatal pathway degeneration in rodent models of Parkinson's disease.Frontiers in cellular neuroscience · 2026
   Article
4. Neuroprotective Effects of VEGF-B in a Murine Model of Aggressive Neuronal Loss with Childhood Onset.International journal of molecular sciences · 2025
   Article
5. Potential Plausible Role of Stem Cell for Treating Depressive Disorder: a Retrospective Review.Molecular neurobiology · 2024
   Review
6. Brain-Derived Neurotrophic Factor - The Protective Agent Against Neurological Disorders.CNS & neurological disorders drug targets · 2024
   Article
7. Bedside to bench: the outlook for psychedelic research.Frontiers in pharmacology · 2023
   Review
8. Baccharin from Brazilian green propolis induces neurotrophic signaling pathways in PC12 cells: potential for axonal and synaptic regeneration.Naunyn-Schmiedeberg's archives of pharmacology · 2022
   Article
9. Strong Binding of Phytochemicals to the Catalytic Domain of Tyrosine Hydroxylase as a Trojan Horse Decreases Dopamine in Dopaminergic Cells: Pharmaceutical Considerations in Schizophrenia and Parkinson's Disease.Current pharmaceutical design · 2022
   Article
10. The Twofold Role of Osteogenic Small Molecules in Parkinson's Disease Therapeutics: Crosstalk of Osteogenesis and Neurogenesis.BioMed research international · 2022
    Review
11. Dietary Plant Polyphenols as the Potential Drugs in Neurodegenerative Diseases: Current Evidence, Advances, and Opportunities.Oxidative medicine and cellular longevity · 2022
    Review
12. Role of Liver Growth Factor (LGF) in Parkinson's Disease: Molecular Insights and Therapeutic Opportunities.Molecular neurobiology · 2021
    Review
13. The Neurotrophic-Like Effect of Carvacrol: Perspective for Axonal and Synaptic Regeneration.Neurotoxicity research · 2021
    Article
14. Co-delivery of glial cell-derived neurotrophic factor (GDNF) and tauroursodeoxycholic acid (TUDCA) from PLGA microspheres: potential combination therapy for retinal diseases.Drug delivery and translational research · 2021
    Article
15. The effect of insomnia on development of Alzheimer's disease.Journal of neuroinflammation · 2020
    Review
16. The potential of bone morphogenetic protein 2 as a neurotrophic factor for Parkinson's disease.Neural regeneration research · 2020
    Review
17. Preclinical Comparison of Stem Cells Secretome and Levodopa Application in a 6-Hydroxydopamine Rat Model of Parkinson's Disease.Cells · 2020
    Article
18. Exercise and Parkinson's Disease.Advances in experimental medicine and biology · 2020
    Review
19. Therapeutic Potential of AAV1-Rheb(S16H) Transduction Against Alzheimer's Disease.Journal of clinical medicine · 2019
    Article
20. α-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease.Acta neuropathologica · 2019
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.